GSK PLC Sponsored ADR $GSK Shares Purchased by NewEdge Advisors LLC

Key Points

• NewEdge Advisors increased its GSK position by 842.9% in the second quarter, adding 852,437 shares to hold 953,574 shares worth approximately $50.0 million. Institutional investors and hedge funds collectively own 15.74% of GSK.
• GSK exceeded quarterly expectations, reporting $1.36 in earnings per share and $11.14 billion in revenue, with revenue up 5.3% year over year. The company guided for fiscal 2026 earnings of $4.90–$5.00 per share.
• GSK raised its quarterly dividend to $0.4515 per share, representing a $1.81 annualized payout and a 3.7% yield. Analysts maintain an overall “Hold” rating, with an average price target of $53.00.

NewEdge Advisors LLC boosted its holdings in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 842.9% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 953,574 shares of the pharmaceutical company's stock after purchasing an additional 852,437 shares during the period. NewEdge Advisors LLC's holdings in GSK were worth $49,986,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Fisher Asset Management LLC lifted its holdings in shares of GSK by 3.0% in the 4th quarter. Fisher Asset Management LLC now owns 33,195,985 shares of the pharmaceutical company's stock valued at $1,627,931,000 after buying an additional 968,370 shares during the period. BI Asset Management Fondsmaeglerselskab A S lifted its holdings in GSK by 2,032.8% in the fourth quarter. BI Asset Management Fondsmaeglerselskab A S now owns 854,331 shares of the pharmaceutical company's stock valued at $41,896,000 after acquiring an additional 814,275 shares during the period. Waverly Advisors LLC lifted its holdings in GSK by 1,372.8% in the second quarter. Waverly Advisors LLC now owns 290,593 shares of the pharmaceutical company's stock valued at $15,233,000 after acquiring an additional 270,863 shares during the period. Kahn Brothers Group Inc. purchased a new stake in GSK in the 2nd quarter worth approximately $8,305,000. Finally, Align Financial LLC purchased a new stake in GSK in the 4th quarter worth approximately $5,628,000. 15.74% of the stock is owned by institutional investors and hedge funds.

GSK Price Performance

GSK stock opened at $48.66 on Thursday. The stock has a market capitalization of $98.42 billion, a P/E ratio of 15.22, a P/E/G ratio of 2.03 and a beta of 0.35. The company's fifty day moving average price is $51.51 and its 200 day moving average price is $52.91. The company has a debt-to-equity ratio of 0.81, a quick ratio of 0.52 and a current ratio of 0.82. GSK PLC Sponsored ADR has a 1 year low of $39.29 and a 1 year high of $61.69.

GSK (NYSE:GSK - Get Free Report) last posted its quarterly earnings data on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share for the quarter, topping analysts' consensus estimates of $1.27 by $0.09. The company had revenue of $11.14 billion during the quarter, compared to analysts' expectations of $11.02 billion. GSK had a net margin of 14.56% and a return on equity of 43.23%. The firm's revenue for the quarter was up 5.3% on a year-over-year basis. During the same period in the prior year, the business posted $0.47 earnings per share. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. As a group, equities research analysts anticipate that GSK PLC Sponsored ADR will post 4.81 earnings per share for the current fiscal year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 8th. Investors of record on Friday, August 14th will be given a dividend of $0.4515 per share. This is a boost from GSK's previous quarterly dividend of $0.44. The ex-dividend date is Friday, August 14th. This represents a $1.81 annualized dividend and a dividend yield of 3.7%. GSK's payout ratio is currently 55.63%.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on GSK shares. Citigroup began coverage on shares of GSK in a report on Friday, July 24th. They set a "neutral" rating for the company. HSBC raised shares of GSK from a "reduce" rating to a "hold" rating in a report on Monday, July 6th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of GSK in a report on Thursday, July 30th. Royal Bank Of Canada assumed coverage on shares of GSK in a research note on Tuesday. They set a "sector perform" rating on the stock. Finally, Jefferies Financial Group upgraded GSK to a "strong-buy" rating in a research report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $53.00.

GSK Profile

GSK plc is a global biopharmaceutical company headquartered in Brentford, England. The company researches, develops and manufactures medicines and vaccines for the prevention and treatment of disease, serving patients and healthcare providers in markets around the world.

GSK focuses on specialty medicines and vaccines in areas including infectious diseases, HIV, respiratory disease, immunology and oncology. Its products include prescription medicines, long-acting treatments and vaccines designed to protect against diseases such as shingles, meningitis, influenza and respiratory syncytial virus (RSV).

The company was formed in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK PLC Sponsored ADR (NYSE:GSK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.